BioCentury | Apr 9, 2021
Management Tracks

Bryce joins Rain as CMO; plus Ichnos, Dementia Discovery Fund, Akoya and more

...was executive director at Pfizer Inc. (NYSE:PFE) and Mansell was SVP of regulatory affairs at Asklepios BioPharmaceutical Inc. BC...
BioCentury | Mar 6, 2021
Deals

How Bayer is building a cell and gene therapy business through deals

...than build them up internally.The acquisition of Asklepios...
BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

...developer Werewolf Therapeutics Inc. named Tim Trost CFO. He was CFO of gene therapy company Asklepios BioPharmaceutical Inc....
BioCentury | Jan 13, 2021
Management Tracks

Spark vet High joins AskBio; plus Rotthier to lead Sanofi API unit and moves at Immunovant, Innocoll

...By Jeff Cranmer, Executive Editor The Asklepios BioPharmaceutical Inc. (AskBio) unit of Bayer AG (Xetra:BAYN) hired Spark Therapeutics...
...to CEO while remaining president. He succeeds Rich Fante at the Gurnet Point portfolio company. Jeff Cranmer Sanofi Asklepios BioPharmaceutical Inc. Innocoll...
BioCentury | Jan 6, 2021
Finance

Senti banks $105M series B as Bayer continues to show enthusiasm for gene and cell therapy biotechs

...platform in fall 2020. It includes the integration of regenerative medicine company BlueRock Therapeutics L.P. and gene therapy company Asklepios BioPharmaceutical Inc. (informally...
BioCentury | Dec 7, 2020
Deals

Adding first CAR T to growing cell therapy unit, Bayer picks Atara’s allogeneic program targeting mesothelin

...progressing the mesothelin programs. When Bayer acquired Asklepios BioPharmaceutical Inc....
BioCentury | Dec 4, 2020
Product Development

Dec. 3 Quick Takes: Moderna, NIH tout persisting neutralizing antibodies from COVID vaccine; plus Bayer, Galapagos, Braeburn, J&J and Equillium

...modalities. It includes the integration of regenerative medicine company BlueRock Therapeutics L.P. and gene therapy company Asklepios BioPharmaceutical Inc. (informally...
BioCentury | Oct 26, 2020
Deals

Bayer’s $2B deal for AskBio follows biotech’s decision to bet on its own pipeline

...technologies, and a revenue-generating CMO business from Asklepios BioPharmaceutical Inc....
...deal is due to close this quarter. Paul Bonanos Asklepios BioPharmaceutical Inc. Bayer...
BioCentury | Oct 24, 2020
Translation in Brief

UNC Chapel Hill Angelman gene therapy rescues motor function; plus data backing planned Pacylex, Kronos clinical trials and more

...C/D Box 115UBE3A (E6AP) – Ubiquitin protein ligase E3A Danielle Golovin PCLX-001 KB-0742 University of North Carolina at Chapel Hill Asklepios BioPharmaceutical Inc. Pacylex...
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...Nardi as VP of manufacturing and engineering operations. Meeks was VP of BD at Synpromics Ltd., which Asklepios BioPharmaceutical Inc....
Items per page:
1 - 10 of 44
BioCentury | Apr 9, 2021
Management Tracks

Bryce joins Rain as CMO; plus Ichnos, Dementia Discovery Fund, Akoya and more

...was executive director at Pfizer Inc. (NYSE:PFE) and Mansell was SVP of regulatory affairs at Asklepios BioPharmaceutical Inc. BC...
BioCentury | Mar 6, 2021
Deals

How Bayer is building a cell and gene therapy business through deals

...than build them up internally.The acquisition of Asklepios...
BioCentury | Feb 9, 2021
Management Tracks

Collins stepping down as Editas CEO, Mallon leaving Ironwood; plus Kite, Werewolf, Vedanta and more

...developer Werewolf Therapeutics Inc. named Tim Trost CFO. He was CFO of gene therapy company Asklepios BioPharmaceutical Inc....
BioCentury | Jan 13, 2021
Management Tracks

Spark vet High joins AskBio; plus Rotthier to lead Sanofi API unit and moves at Immunovant, Innocoll

...By Jeff Cranmer, Executive Editor The Asklepios BioPharmaceutical Inc. (AskBio) unit of Bayer AG (Xetra:BAYN) hired Spark Therapeutics...
...to CEO while remaining president. He succeeds Rich Fante at the Gurnet Point portfolio company. Jeff Cranmer Sanofi Asklepios BioPharmaceutical Inc. Innocoll...
BioCentury | Jan 6, 2021
Finance

Senti banks $105M series B as Bayer continues to show enthusiasm for gene and cell therapy biotechs

...platform in fall 2020. It includes the integration of regenerative medicine company BlueRock Therapeutics L.P. and gene therapy company Asklepios BioPharmaceutical Inc. (informally...
BioCentury | Dec 7, 2020
Deals

Adding first CAR T to growing cell therapy unit, Bayer picks Atara’s allogeneic program targeting mesothelin

...progressing the mesothelin programs. When Bayer acquired Asklepios BioPharmaceutical Inc....
BioCentury | Dec 4, 2020
Product Development

Dec. 3 Quick Takes: Moderna, NIH tout persisting neutralizing antibodies from COVID vaccine; plus Bayer, Galapagos, Braeburn, J&J and Equillium

...modalities. It includes the integration of regenerative medicine company BlueRock Therapeutics L.P. and gene therapy company Asklepios BioPharmaceutical Inc. (informally...
BioCentury | Oct 26, 2020
Deals

Bayer’s $2B deal for AskBio follows biotech’s decision to bet on its own pipeline

...technologies, and a revenue-generating CMO business from Asklepios BioPharmaceutical Inc....
...deal is due to close this quarter. Paul Bonanos Asklepios BioPharmaceutical Inc. Bayer...
BioCentury | Oct 24, 2020
Translation in Brief

UNC Chapel Hill Angelman gene therapy rescues motor function; plus data backing planned Pacylex, Kronos clinical trials and more

...C/D Box 115UBE3A (E6AP) – Ubiquitin protein ligase E3A Danielle Golovin PCLX-001 KB-0742 University of North Carolina at Chapel Hill Asklepios BioPharmaceutical Inc. Pacylex...
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...Nardi as VP of manufacturing and engineering operations. Meeks was VP of BD at Synpromics Ltd., which Asklepios BioPharmaceutical Inc....
Items per page:
1 - 10 of 44